Verlukast — predicted protein targets

Known targets — ChEMBL curated mechanism

ABCC8 ACE ADORA1 ADORA2A ADORA2B ADORA3 ALDH5A1 ALOX5 ALOX5AP ATP4A ATP4B BRAF CA1 CA12 CA2 CA4 CYSLTR1 DHFR DPEP1 EDNRA EDNRB ESR2 F10 FDPS FGF1 GABBR1 GABBR2 GABRA1 GABRA2 GABRA3 GABRA4 GABRA5 GABRA6 GABRB1 GABRB2 GABRB3 GABRD GABRE GABRG1 GABRG2 GABRG3 GABRP GABRQ GART GNRHR GSC1 HMGCR IMPDH1 IMPDH2 KCNJ11 LY96 NOD2 NR3C1 NS3 NS4A NS5b P2RY1 P2RY12 P2RY2 P2RY4 P2RY6 PBP2X PDE3A PDE3B PDE4A PDE4B PDE4C PDE4D PDK1 PDK2 PDK3 PDK4 PPARG PPAT PTGIR PTGS1 PTGS2 RAF1 RYR1 RYR3 SCN10A SCN11A SCN1A SCN2A SCN3A SCN4A SCN5A SCN7A SCN8A SCN9A SERPINC1 SLC12A1 SLC12A3 SYK THRA THRB TLR3 TLR4 TLR9 TUBA1A TUBA1B TUBA1C TUBA3C TUBA3E TUBA4A TUBB TUBB1 TUBB2A TUBB2B TUBB3 TUBB4A TUBB4B TUBB6 TUBB8 TYMS VKORC1 XDH bla blaIMP-1 blaOXA-33 blaOXA-58 blaT-3 blaT-4 blaT-5 blaT-6 dacA dacB dacC folA folP folP1 ftsI fusA gag gyrA gyrB mecA mrcA mrcB mrdA pbp1a pbp1b pbp2 pbp2a pbp2b pbp3 pbp4 pbpA pbpB pbpC pbpF pol ponB rplA rplB rplC rplD rplE rplF rplJ rplK rplL rplM rplN rplO rplP rplQ rplR rplS rplT rplU rplV rplW rplX rplY rpmA rpmB rpmC rpmD rpmE rpmF rpmG rpmH rpmI rpmJ rpoA rpoB rpoC rpoZ rpsA rpsB rpsC rpsD rpsE rpsF rpsG rpsH rpsI rpsJ rpsK rpsL rpsM rpsN rpsO rpsP rpsQ rpsR rpsS rpsT rpsU ykgM ykgO

The experimentally established mechanism targets of Verlukast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

	gene	UniProt	supporting neighbours	confidence
▸	CYSLTR1 known ✓	Q9Y271	6/20	1.00

▸	ABCC1	P33527	4/20	1.00

▸	CYSLTR2	Q9NS75	4/20	1.00

▸	ABCC2	Q92887	3/20	1.00

▸	MEN1	O00255	1/20	0.84

▸	ABCC3	O15438	1/20	0.84

▸	ABCC4	O15439	1/20	0.84

▸	ABCC5	O15440	1/20	0.84

▸	SLCO2B1	O94956	1/20	0.84

▸	ABCB11	O95342	1/20	0.84

▸	KMT2A	Q03164	1/20	0.84

▸	SLCO1B3	Q9NPD5	1/20	0.84

▸	ABCG2	Q9UNQ0	1/20	0.84

▸	SLCO1B1	Q9Y6L6	1/20	0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Verlukast SCHEMBL26976748	1.00	CYSLTR1 (1.00)	CYSLTR1ABCC1CYSLTR2ABCC2MEN1
Verlukast SCHEMBL31237455	1.00	CYSLTR1 (1.00)	CYSLTR1ABCC1CYSLTR2ABCC2MEN1
SCHEMBL17833480	0.92	CYSLTR1 (0.89)	CYSLTR1ABCC1CYSLTR2ABCC2MEN1
Verlukast SCHEMBL37247	0.92	CYSLTR1 (1.00)	CYSLTR1ABCC1CYSLTR2ABCC2MEN1
Verlukast SCHEMBL2729252	0.92	CYSLTR1 (1.00)	CYSLTR1ABCC1CYSLTR2ABCC2MEN1
Mk-571 SCHEMBL9231584	0.92	CYSLTR1 (1.00)	CYSLTR1ABCC1CYSLTR2ABCC2MEN1
Verlukast SCHEMBL37246	0.92	CYSLTR1 (1.00)	CYSLTR1ABCC1CYSLTR2ABCC2MEN1
Mk-571 SCHEMBL30509651	0.92	CYSLTR1 (1.00)	CYSLTR1ABCC1CYSLTR2ABCC2MEN1
Verlukast SCHEMBL156454	0.91	CYSLTR1 (0.98)	CYSLTR1ABCC1CYSLTR2ABCC2MEN1
Mk-571 SCHEMBL156452	0.91	CYSLTR1 (0.98)	CYSLTR1ABCC1CYSLTR2ABCC2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20180369321-A1	COMPOSITIONS AND METHODS FOR TREATING CONDITIONS RELATED TO ADRENOCORTICAL ACTIVITY AND/OR EXCESSIVE STEROID PRODUCTION	THE REGENTS OF THE UNIVERSITY OF MICHIGAN	2018-12-27	—	—	US	claimed
US-4851409-A	LEUKOTRIENE ANTAGONIST, ANTIASTHMA, ANTIALLERGEN, ANTIINFLAMMATORY, CYTOPROTECTIVE	MERCK FROSST CANADA INC. (CA)	1989-07-25	—	—	US	claimed
US-20250092042-A1	HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF	NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.	2025-03-20	—	—	US	disclosed
US-12157737-B2	Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof	NOVARTIS AG (CH)	2024-12-03	—	—	US	disclosed
CN-118746695-A	Screening method of adenosine triphosphate binding cassette transporter substrate	清华大学	2024-10-08	—	—	CN	disclosed
US-20240043425-A1	HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF	NOVARTIS AG (CH)	2024-02-08	—	—	US	disclosed
US-11708366-B2	Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof	NOVARTIS AG (CH)	2023-07-25	—	—	US	disclosed
EP-4196478-A1	HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF	Novartis AG (CH)	2023-06-21	—	—	EP	disclosed
US-20220347309-A1	PYRROLOBENZODIAZEPINE RESISTANCE	OWL ROCK OPPORTUNISTIC MASTER FUND I, L.P.	2022-11-03	—	—	US	disclosed
WO-2022034529-A1	HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF	NOVARTIS AG (CH)	2022-02-17	—	—	WO	disclosed
US-20220048909-A1	HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF	NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.	2022-02-17	—	—	US	disclosed
WO-2005115467-A1	COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS	ALMIRALL PRODESFARMA S.A. (ES)	2005-12-08	—	—	WO	disclosed
WO-2005115466-A1	COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND CORTICOSTEROIDS	ALMIRALL PRODESFARMA S.A. (ES)	2005-12-08	—	—	WO	disclosed
WO-2005115462-A1	COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS	ALMIRALL PRODESFARMA S.A. (ES)	2005-12-08	—	—	WO	disclosed
WO-2005115465-A1	COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND PDE4 INHIBITORS	ALMIRALL PRODESFARMA S.A. (ES)	2005-12-08	—	—	WO	disclosed
US-20050267135-A1	Combinations comprising antimuscarinic agents and PDE4 inhibitors	ESCARDO JORDI G	2005-12-01	—	—	US	disclosed
US-20050267078-A1	Combinations comprising antimuscarinic agents and beta-adrenergic agonists	GRAS ESCARDO JORDI	2005-12-01	—	—	US	disclosed
US-5428171-A	Leukotrienes antagonist; antiasthmatic, antiallergic, anti-inflammatory and cytoprotective agent	MERCK FROSST CANADA, INC. (CA)	1995-06-27	—	—	US	disclosed
US-4851409-A	LEUKOTRIENE ANTAGONIST, ANTIASTHMA, ANTIALLERGEN, ANTIINFLAMMATORY, CYTOPROTECTIVE	MERCK FROSST CANADA INC. (CA)	1989-07-25	—	—	US	disclosed
EP-0233763-A2	2-Substituted quinoline dioic acids	MERCK FROSST CANADA INC. (CA)	1987-08-26	—	—	EP	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-12157737-B2	Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof	REN, NR3C2, PKD1	CYSLTR1 2201/4885ABCC1 254/4885CYSLTR2 2646/4885
US-11708366-B2	Heteroaryl substituted spiropiperidinyl derivatives and pharmaceutical uses thereof	REN, NR3C2, PKD1	CYSLTR1 2201/4885ABCC1 254/4885CYSLTR2 2646/4885
US-20220347309-A1	PYRROLOBENZODIAZEPINE RESISTANCE	DCTD, FANCD2, CD79B	CYSLTR1 3593/4885ABCC1 152/4885CYSLTR2 2824/4885
US-20240043425-A1	HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF	REN, NR3C2, PKD1	CYSLTR1 2201/4885ABCC1 254/4885CYSLTR2 2646/4885
US-20050267135-A1	Combinations comprising antimuscarinic agents and PDE4 inhibitors	CHRM3, PDE4A, CHRM4	CYSLTR1 197/4885ABCC1 1464/4885CYSLTR2 186/4885
US-20050267078-A1	Combinations comprising antimuscarinic agents and beta-adrenergic agonists	ADRB2, ADRB3, CHRM3	CYSLTR1 92/4885ABCC1 1053/4885CYSLTR2 54/4885
US-20250092042-A1	HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF	REN, PKD1, PKD2	CYSLTR1 2354/4885ABCC1 245/4885CYSLTR2 2928/4885
US-20220048909-A1	HETEROARYL SUBSTITUTED SPIROPIPERIDINYL DERIVATIVES AND PHARMACEUTICAL USES THEREOF	REN, NR3C2, PKD1	CYSLTR1 2201/4885ABCC1 254/4885CYSLTR2 2646/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.